X

Hematology Advisor

Hematology Advisor
Alemtuzumab as Part of Conditioning Therapy for Graft-vs-Host Disease in Children and Young Adults

According to a new study, conditioning chemotherapy that contains alemtuzumab may improve outcomes related to GvHD and relapse in children and young adults with hematologic malignancies.

Hematology Advisor
05/05/2021
Abatacept May Be Additional Prophylaxis for Graft vs Host Disease in Patients With Beta-Thalassemia

Abatacept added to routine prophylaxis for acute GvHD reduces incidence of severe GvHD at 100 days in children with transfusion-dependent beta-thalassemia.

Hematology Advisor
04/15/2021
Subscribe to Hematology Advisor

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39